24 March 2023 – PLC recognizes Neurelis’ recent announcement concerning first dosing of their first-in-human study to treat patients with cerebral cavernous malformation (CCM) with NRL-1049, a Rho kinase (ROCK) inhibitor. PLC has supported Neurelis with their Regulatory filings for NRL-1049 from inception of the program.
NEURELIS ANNOUNCES FIRST HEALTHY SUBJECTS DOSED IN INVESTIGATIONAL STUDY OF NRL-1049, A RHO KINASE (ROCK) INHIBITOR WITH POTENTIAL TO TREAT CEREBRAL CAVERNOUS MALFORMATIONS
- First in human study will evaluate safety, tolerability, and pharmacokinetic parameters of NRL-1049, a Rho kinase (ROCK) inhibitor
